NIA put dementia-subtype data gaps on its March 2026 agenda, yet clinic records still miss many Lewy body and mixed cases. Adults with memory concerns will therefore see little change in diagnosis or support right now.
ADRD means Alzheimer's disease and related dementias. For care, the subtype name matters less than symptoms, safety, and daily help. Better records and biomarkers may improve future choices, but current visits still rely on clinical judgment and caregiver input.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How often are subtypes missed?
- What does ADRD include?
- What did NIA review in March 2026?
- What should you do at your next visit?
How often are subtypes missed?
PubMed Central reported an analysis of 8,188 decedents from 2005-2024 in the journal analysis. A premortem Lewy body diagnosis was highly specific but missed more than half of autopsy-confirmed cases, with Alzheimer's the commonest misdiagnosis.
Frontiers in Aging Neuroscience reported 1,920 participants from 2005-2019 in the NACC study. Over 61% with autopsy-confirmed Alzheimer's plus Lewy body disease had been called Alzheimer's alone, showing poor sensitivity for mixed disease. A person with acting-out dreams, visual hallucinations, or Parkinson-like stiffness may still leave clinic with only an Alzheimer's label.
What does ADRD include?
NIA defines ADRD research as covering Alzheimer's plus frontotemporal dementia, Lewy body dementias, vascular contributions, and multiple-etiology dementias. These conditions often share memory loss, confusion, and behavior change, plus overlapping brain pathologies.
The 2025 ADRD Summit set priorities for frontotemporal degeneration, Lewy body dementia, multiple-etiology dementias, and vascular impairment, according to BrightFocus Foundation. A stated priority was better biomarkers for mixed-etiology disease involving Lewy pathology. Until those tools reach clinics, mixed disease often looks like one disease.
What did NIA review in March 2026?
The Roybal NIA Research Centers reported that NIA's Dementia Care and Caregiving Research Summit was held virtually March 17-19, 2026 in the summit announcement. It reviewed progress and needs of people with dementia, care partners, communities, and health systems.
The same summit agenda explicitly included advances in AD/ADRD data infrastructure to support dementia care and caregiving research. Stronger infrastructure means more complete diagnosis codes, linked records, and samples that reflect Lewy body, vascular, and mixed cases. Those fixes help future research before they change any single patient's plan.
What should you do at your next visit?
The NIA IMPACT Collaboratory reported D-CARE, the largest pragmatic randomized dementia-care trial to date, in the trial summary. It found no difference in patient behavioral symptoms or caregiver stress among health-system, community-based, and usual care over 18 months.
New program names alone did not improve outcomes. Bring details that help separate subtypes and guide safety now: Ask the clinician what working diagnosis is being used, what would change it, and when to return sooner.
- sleep behavior, hallucinations, fainting, falls, and sensitivity to sedating drugs
- blood pressure, stroke, diabetes, and all prescription and over-the-counter medicines
- daily function, driving, cooking, wandering, and who can help each week
You Might Also Like
- Privacy and Data Access Gaps in 2026 Dementia Research: Why the Findings May Not Change Care Yet for Adults With Memory Concerns
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Study Design and Evidence Limits for Adult Children
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Questions Adult Children Can Ask About the Research
